Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease

Nature Medicine

Volumn 8, Issue 12, 2002, Pages 1383-1389

  Reiter, Christopher D ^a,b   Wang, Xunde ^a   Tanus Santos, Jose E ^a,b   Hogg, Neil ^c   Cannon III, Richard O ^d   Schechter, Alan N ^b   Gladwin, Mark T ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c FREE RADICAL RESEARCH CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S; NITRIC OXIDE DONOR;

ADULT; ARTICLE; AUTOOXIDATION; BIOAVAILABILITY; CELL FREE SYSTEM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ERYTHROCYTE; FOREARM BLOOD FLOW; HEMOLYSIS; HOMEOSTASIS; HUMAN; OXIDATION; PHENOTYPE; POLYMERIZATION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STOICHIOMETRY; VASOCONSTRICTION;

EID: 0036908599     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1202-799     Document Type: Article

References (48)

1. Eich, R.F. et al. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35, 6976-6983 (1996).
2. Herold, S., Exner, M. & Nauser, T. Kinetic and mechanistic studies of the NO-mediated oxidation of oxymyoglobin and oxyhemoglobin. Biochemistry 40, 3385-3395 (2001).
3. Gibson, Q. & Roughton, F.J.W. The kinetics and equilibria of the reactions of nitric oxide with sheep hemoglobin. J. Physiol. (Lond). 136, 507-526 (1957).
4. Cassoly, R, & Gibson, Q. Conformation, co-operativity and ligand binding in human hemoglobin. J. Mol. Biol. 91, 301-313 (1975).
5. Carlsen, E. & Comroe, J.H. The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. J. Gen. Physiol. 42, 83-107 (1958).
6. Liu, X. et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. J. Biol. Chem. 273, 18709-18713 (1998).
7. Lancaster, J.R. Jr. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1, 18-30 (1997).
8. Vaughn, M.W. Kuo, L. & Liao, J.C. Effective diffusion distance of nitric oxide in the microcirculation. Am. J. Physiol. 274, H1705-H1714 (1998).
9. Hess, J.R., MacDonald, V.W. & Brinkley, W.W. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J. Appl. Physiol. 74, 1769-1778 (1993).
10. Lee, R., Neya, K., Svizzero, T.A. & Vlahakes, G.J. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. 79, 236-242 (1995).
11. de Figueiredo, L.F. et al. Pulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes. J. Trauma 42, 847-856 (1997).
12. Vogel, W.M., Dennis, R.C., Cassidy, G., Apstein, C.S. & Valeri, C.R. Coronary constrictor effect of stroma-free hemoglobin solutions. Am. J. Physiol. 251, H413-H420 (1986).
13. Ulatowski, J.A. et al. Regional blood flow alterations after bovine fumaryl β-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition. Crit. Care Med. 24, 558-565 (1996).
14. Murray, J.A. et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 109, 1241-1248 (1995).
15. Sloan, E.P. et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial. JAMA 282, 1857-1864 (1999).
16. Doherty, D.H. et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nature Biotechnol. 16, 672-676 (1998).
17. Vaughn, M.W., Huang, K.T., Kuo, L. & Liao, J.C. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J. Biol. Chem. 275, 2342-2348 (2000).
18. Huang, K.T. et al. Modulation of nitric oxide bioavailability by erythrocytes. Proc. Natl. Acad. Sci. USA 98, 11771-11776 (2001).
19. Coin, J.T. & Olson, J.S. The rate of oxygen uptake by human red blood cells. J. Biol. Chem. 254, 1178-1190 (1979).
20. Butler, A.R., Megson, I.L. & Wright, P.G. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim. Biophys. Acta 1425, 168-176 (1998).
21. Liao, J.C., Hein, T.W., Vaughn, M.W., Huang, K.T. & Kuo, L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc. Natl. Acad. Sci. USA 96, 8757-8761 (1999).
22. Poh, U. & Lamontagne, D. Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res. Cardiol. 86, 97-105 (1991).
23. Bensinger, T.A., & Gillette, P.N. Hemolysis in sickle-cell disease. Arch. Intern. Med. 133, 624-631 (1974).
24. Browne, P., Shalev, O. & Hebbel, R.P. The molecular pathobiology of cell membrane iron: The sickle red cell as a model. Free Radic. Biol. Med. 24, 1040-1048 (1998).
25. Hebbel, R.P., Morgan, W.T., Eaton, I.W. & Hedlund, B.E. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl. Acad. Sci. USA 85, 237-241 (1988).
26. Naumann, H.N., Diggs, L.W., Barreras, L. & Williams, B.J. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am. J. Clin. Pathol. 56, 137-147 (1971).
27. Kaul, D.K. & Hebbel, R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 106, 411-420 (2000).
28. De Caterina, R. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60-68 (1995).
29. Setty, B.N. & Stuart, M.J. Vascular cell adhesion mole cule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium; Potential role in sickle-cell disease. Blood 88, 2311-2320 (1996).
30. Han, T.H., Hyduke, D.R., Vaughn, M.W., Fukuto, J.M. & Liao, J.C. Nitric oxide reaction with red blood cells and hemoglobin under heterogeneous conditions. Proc. Natl. Acad. Sci. USA 99, 7763-7768 (2002).
31. Ford, P.C., Wink, D.A. & Stanbury, D.M. Autoxidation kinetics of aqueous nitric oxide. FEBS Lett. 326, 1-3 (1993).
32. Hogg, N. The biochemistry and physiology of S-nitrosothiols. Annu. Rev. Pharmacol. Toxicol. 42, 585-600 (2002).
33. Gladwin, M.T. et al. Role of circulating nitrite and β-nitrosohemoglobin in the regulation of regional blood flow in humans. Proc. Natl. Acad. Sci. USA 97, 11482-11487 (2000).
34. Gladwin, M.T. et al. Relative role of heme nitrosylation and β-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc. Natl. Acad. Sci. USA 97, 9943-9948 (2000).
35. McMahon, T.J. et al. Nitric oxide in the human respiratory cycle. Nature Med. 8, 711-717 (2002).
36. Ruschitzka, F.T. et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 97, 11609-11613 (2000).
37. Banerjee, D., Rodriguez, M., Nag, M. & Adamson, J.W. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int. 57, 1895-1904 (2000).
38. Kristiansen, M. et al. Identification of the haemoglobin scavenger receptor. Nature 409, 198-201 (2001).
39. Belhassen, L. et al. Endothelial dysfunction in patients with sickle-cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 97, 1584-1589 (2001).
40. Nath, K.A. et al. Mechanisms of vascular instability in a transgenic mouse model of sickle-cell disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1949-R1955 (2000).
41. Kaul, D.K., Liu, X.D., Fabry, M.E. & Nagel, R.L. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am. J. Physiol. Heart Circ. Physiol. 278, H1799-H1806 (2000).
42. Asian, M. et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle-cell disease. Proc. Natl. Acad. Sci. USA 98, 15215-15220 (2001).
43. Cannon, R.O. III et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J. Clin. Invest. 108, 279-287 (2001).
44. Rassaf, T. et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J. Clin. Invest. 109, 1241-1248 (2002).
45. Morris, C.R. et al. Arginine therapy: A novel strategy to induce nitric oxide production in sickle-cell disease. Br. J. Haematol. 111, 498-500 (2000).
46. Gladwin, M.T. et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J. Clin. Invest. 104, 937-945 (1999).
47. Marley, R., Feelisch, M., Holt, S. & Moore, K. A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. Free Radic. Res. 32, 1-9 (2000).
48. 2/NO-linked allosteric function. J. Biol. Chem. 277, 27818-27828 (2002).